https://scholars.lib.ntu.edu.tw/handle/123456789/414002
標題: | Adlay bran oil suppresses hepatic gluconeogenesis and attenuates hyperlipidemia in type 2 diabetes rats | 作者: | Tseng, Yi Han CHING-WEN CHANG Chiang, Wenchang SHU-CHEN HSIEH |
關鍵字: | adlay bran oil | blood glucose | diabetes;adlay bran oil; blood glucose; diabetes | 公開日期: | 1-一月-2019 | 出版社: | MARY ANN LIEBERT, INC | 卷: | 22 | 期: | 1 | 起(迄)頁: | 22 | 來源出版物: | Journal of Medicinal Food | 摘要: | © Copyright 2019, Mary Ann Liebert, Inc., publishers and Korean Society of Food Science and Nutrition 2019. This study aimed to examine the antidiabetic effects of various concentrations of adlay bran oil (ABO) in high fat diet and streptozotocin-induced diabetic rats. Dietary supplementation with 10% ABO for 4 weeks effectively decreased the blood triacylglycerol, glucose, and total cholesterol levels in diabetic rats, although body weight remained the same. The mRNA and protein expressions of hepatic glucose transporter 2 (GLUT-2) and phosphoenolpyruvate carboxykinase (PEPCK) were increased and that of glucokinase (GCK) were decreased in diabetic rats. However, 10% ABO treatment reduced the mRNA and protein expressions of GLUT-2 and PEPCK and elevated the expression of hepatic GCK in diabetic rats. Thus, ABO enhanced hepatic glucose metabolism to decrease blood glucose in diabetic rats. In addition, 10% ABO supplementation increased the expression of phosphorylated protein kinase B (Akt) relative to the total Akt levels in the muscles of diabetic rats, indicating enhanced insulin sensitivity. The results indicate that ABO displays a potential for improving hyperlipidemia and hyperglycemia in diabetes by enhancing insulin sensitivity and hepatic glucose metabolism. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/414002 | ISSN: | 1096620X | DOI: | https://api.elsevier.com/content/abstract/scopus_id/85060375127 10.1089/jmf.2018.4237 |
SDG/關鍵字: | adlay bran oil; antidiabetic agent; cholesterol; glucokinase; glucose; glucose transporter 2; insulin; phosphoenolpyruvate carboxykinase (GTP); protein kinase B; triacylglycerol; unclassified drug; vegetable oil; antidiabetic agent; antilipemic agent; glucokinase; glucose transporter 2; lipid; messenger RNA; phosphoenolpyruvate carboxykinase (ATP); protein kinase B; Slc2a2 protein, rat; vegetable oil; animal experiment; animal model; antidiabetic activity; Article; body weight; cholesterol blood level; controlled study; diet supplementation; food intake; gene expression; gluconeogenesis; glucose blood level; glucose metabolism; hyperlipidemia; insulin sensitivity; insulin signaling; lipid diet; male; non insulin dependent diabetes mellitus; nonhuman; priority journal; protein expression; streptozotocin-induced diabetes mellitus; total cholesterol level; triacylglycerol blood level; animal; blood; chemistry; Coix; complication; drug effect; experimental diabetes mellitus; gluconeogenesis; hyperglycemia; hyperlipidemia; insulin resistance; liver; metabolism; muscle; non insulin dependent diabetes mellitus; phytotherapy; Sprague Dawley rat; Animals; Blood Glucose; Coix; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucokinase; Gluconeogenesis; Glucose Transporter Type 2; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lipids; Liver; Male; Muscles; Phosphoenolpyruvate Carboxykinase (ATP); Phytotherapy; Plant Oils; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; RNA, Messenger |
顯示於: | 食品科技研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。